nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2012 | Original Paper

ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer

verfasst von: Gianluigi Mazzoccoli, Valerio Pazienza, Anna Panza, Maria Rosa Valvano, Giorgia Benegiamo, Manlio Vinciguerra, Angelo Andriulli, Ada Piepoli

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cathepsin and plasmin may favor cancer cell invasion degrading extracellular matrix. Plasmin formation from plasminogen is regulated by plasminogen activator inhibitor type-1 (PAI-1). ARNTL2 activates the promoters of the PAI-1 gene, officially called SERPINE1, driving the circadian variation in circulating PAI-1 levels.

Methods

We evaluated ARNTL2 and SERPINE1 expression in 50 colorectal cancer specimens and adjacent normal tissue and in colon cancer cell lines.

Results

We found up-regulation of ARNTL2 (P = 0.004) and SERPINE1 (P = 0.002) in tumor tissue. A statistically significant association was found between high ARNTL2 mRNA levels and vascular invasion (P < 0.0001), and between high SERPINE1 mRNA levels and microsatellite instability (MSI-H and MSI-L, P = 0.025). Sorting the subjects into quartile groups, a statistically significant association was found between high ARNTL2 expression and lymph node involvement (P < 0.001), between high SERPINE1 expression and grading (P < 0.001) and between high SERPINE1 expression and MSI H–L (P < 0.0001). In SW480 cells, a more proliferative model compared to CaCo2 cells, there were higher mRNA levels of ARNTL2 (P < 0.001) and SERPINE1 (P = 0.001).

Conclusion

ARNTL2 and SERPINE1 expression is increased in colorectal cancer and in a highly proliferative colon cancer cell line and is related to tumor invasiveness and aggressiveness.

Agostino PV, Harrington ME, Ralph MR, Golombek DA (2009) Casein kinase-1-epsilon (CK1epsilon) and circadian photic responses in hamsters. Chronobiol Int 26:126–133PubMedCrossRef

Andreasen PA (2007) PAI-1—a potential therapeutic target in cancer. Curr Drug Targets 8(9):1030–1041PubMedCrossRef

Angleton P, Chandler WL, Schmer G (1989) Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79:101–106PubMedCrossRef

Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noël A (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152(4):777–784PubMedCrossRef

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814–1821PubMedCrossRef

Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H (2006) Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106:1026–1035PubMedCrossRef

Boland CR, Thibodeau SN, Hamilton SR (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257PubMed

Cale JM, Li SH, Warnock M, Su EJ, North PR, Sanders KL, Puscau MM, Emal CD, Lawrence DA (2010) Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 285(11):7892–7902PubMedCrossRef

Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Norat T (2011) Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One 6:e20456PubMedCrossRef

Charfi C, Voisin V, Levros LC Jr, Edouard E, Rassart E (2011) Gene profiling of Graffi murine leukemia virus-induced lymphoid leukemias: identification of leukemia markers and Fmn2 as a potential oncogene. Blood 117(6):1899–1910PubMedCrossRef

Chu G, Yoshida K, Narahara S, Uchikawa M, Kawamura M, Yamauchi N, Xi Y, Shigeyoshi Y, Hashimoto S, Hattori MA (2011) Alterations of circadian clockworks during differentiation and apoptosis of rat ovarian cells. Chronobiol Int 28:477–487PubMedCrossRef

Compton CC (2003) Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 16:376–388PubMedCrossRef

Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375:1030–1047PubMedCrossRef

Czekay RP, Loskutoff DJ (2009) Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol 220(3):655–663PubMedCrossRef

Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ (2003) Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160(5):781–791PubMedCrossRef

Dardente H, Cermakian N (2007) Molecular circadian rhythms in central and peripheral clocks in mammals. Chronobiol Int 24:195–213PubMedCrossRef

Darmoul D, Marie J-C, Devaud H, Gratio V, Laburthe M (2001) Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer 85:772–779PubMedCrossRef

Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schalfeldt B, Diamandis EP, Schmitt M (2006) Disease processes may be reflected by correlations among tissue kallikrein proteases but not proteolytic factors UPA and PAI-1 in primary ovarian carcinoma. Biol Chem 387:1121–1128PubMedCrossRef

Duguay D, Cermakian N (2009) The crosstalk between physiology and circadian clock proteins. Chronobiol Int 26:1479–1513PubMedCrossRef

Dutta P, Koch A, Breyer B, Schneider H, Dittrich-Breiholz O, Kracht M, Tamura T (2011) Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis. BMC Genomics 12:196PubMedCrossRef

Edery I (2000) Circadian rhythms in a nutshell. Physiol Genomics 3:59–74PubMed

Einholm AP, Pedersen KE, Wind T, Kulig P, Overgaard MT, Jensen JK, Bødker JS, Christensen A, Charlton P, Andreasen PA (2003) Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J 373(Pt 3):723–732PubMedCrossRef

Erren TC, Groß JV, Meyer-Rochow VB (2011) Light, clocks, mood, and cancer: consolidation and novel tests of latitude and instability hypotheses. Chronobiol Int 28:471–473PubMedCrossRef

Filipski E, King VM, Li XM, Granda TG, Mormont MC, Liu X (2002) Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 94:690–697PubMedCrossRef

Filipski E, King VM, Etienne MC, Li XM, Claustrat B, Granda TG (2004) Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice. Am J Physiol Regul Integr Comp Physiol 287:R844–R851PubMedCrossRef

Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nature Rev Cancer 3:350–361CrossRef

Fu L, Pelicano H, Liu J, Huang P, Lee CC (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50PubMedCrossRef

Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB, Verspaget HW (1997) Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes’s stage B and C colorectal cancer. Br J Cancer 75:1793–1801PubMedCrossRef

Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4:649–661PubMedCrossRef

Hayashida S, Kuramoto Y, Koyanagi S, Oishi K, Fujiki J, Matsunaga N, Ikeda E, Ohdo S, Shimeno H, Soeda S (2010) Proxisome proliferator-activated receptor-α mediates high-fat, diet-enhanced daily oscillation of plasminogen activator inhibitor-1 activity in mice. Chronobiol Int 27:1735–1753PubMedCrossRef

Huang TS, Grodeland G, Sleire L, Wang MY, Kvalheim G, Laerum OD (2009) Induction of circadian rhythm in cultured human mesenchymal stem cells by serum shock and cAMP analogs in vitro. Chronobiol Int 26:242–257PubMedCrossRef

Ikeda M, Yu W, Hirai M, Ebisawa T, Honma S, Yoshimura K, Honma KI, Nomura M (2000) cDNA cloning of a novel bHLH-PAS transcription factor superfamily gene, BMAL2: its mRNA expression, subcellular distribution, and chromosomal localization. Biochem Biophys Res Commun 275:493–502PubMedCrossRef

Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Lévi F (2009) Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int 26:1169–1188PubMed

Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T (2005) Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer and effects of Helicobacter pylori. Scand J Gastroenterol 40:783–793PubMedCrossRef

Jensen SA, Vainer B, Kruhøffer M, Sørensen JB (2009) Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer 20:e25CrossRef

Jud C, Chappuis S, Revell VL, Sletten TL, Saaltink DJ, Cajochen C, Skene DJ, Albrecht U (2009) Age-dependent alterations in human PER2 levels after early morning blue light exposure. Chronobiol Int 26:1462–1469PubMedCrossRef

Khapre RV, Samsa WE, Kondratov RV (2010) Circadian regulation of cell cycle: molecular connections between aging and the circadian clock. Ann Med 42(6):404–415PubMedCrossRef

Kloog I, Haim A, Stevens RG, Portnov BA (2009) Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men. Chronobiol Int 26:108–125PubMedCrossRef

Koch JM, Hagenauer MH, Lee TM (2009) The response of Per1 to light in the suprachiasmatic nucleus of the diurnal degu (Octodon degus). Chronobiol Int 26:1263–1271PubMed

Kurnik PB (1995) Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 91:1341–1346PubMed

Leibetseder V, Humpeler S, Svoboda M, Schmid D, Thalhammer T, Zuckermann A, Marktl W, Ekmekcioglu C (2009) Clock genes display rhythmic expression in human hearts. Chronobiol Int 26:621–636PubMedCrossRef

Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA (2006) Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 4(12):2710–2715PubMedCrossRef

Lemmer B (2009) Discoveries of rhythms in human biological functions: a historical review. Chronobiol Int 26:1019–1068PubMed

Lindberg P, Larsson A, Nielsen BS (2006) Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin γ-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer 118:2948–2956PubMedCrossRef

Liu S, Cai Y, Sothern RB, Guan Y, Chan P (2007) Chronobiological analysis of circadian patterns in transcription of seven key clock genes in six peripheral tissues in mice. Chronobiol Int 24:793–820PubMedCrossRef

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCt method. Methods 25:402–408PubMedCrossRef

Lowrey PL, Takahashi JS (2000) Genetics of the mammalian circadian system: photic entrainment, circadian pacemaker mechanisms, and posttranslational regulation. Annu Rev Genet 34:533–562PubMedCrossRef

Luo Y, Tian W, Cai L, Wang Y, Zhang J, Teng H, Du J, Sun ZS (2009) Expression profiling reveals a positive regulation by mPer2 on circadian rhythm of cytotoxicity receptors: Ly49C and Nkg2d. Chronobiol Int 26:1514–1544PubMedCrossRef

Madsen CD, Sidenius N (2008) The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 87(8–9):617–629PubMedCrossRef

Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME (2000) CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 275:36847–36851PubMedCrossRef

Märkl B, Renk I, Oruzio DV, Jähnig H, Schenkirsch G, Schöler C, Ehret W, Arnholdt HM, Anthuber M, Spatz H (2010) Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol 102:235–241PubMedCrossRef

Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H (2003) Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255–259PubMedCrossRef

Mazzoccoli G (2011) The timing clockwork of life. J Biol Regul Homeost Agents 25:137–143PubMed

Nagoshi E, Saini C, Bauer C, Laroche T, Naef F, Schibler U (2004) Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 119:693–705PubMedCrossRef

Nielsen HJ, Pappot H, Christensen J, Brünner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøndahl-Hansen J (1998) Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 316:829–830PubMedCrossRef

Offersen BV, Pfeiffer P, Andreasen P, Overgaard J (2007) Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in normal-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 43:43–50CrossRef

Oishi K (2009) Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens 31:208–219PubMedCrossRef

Oishi K, Miyazaki K, Uchida D, Ohkura N, Wakabayashi M, Doi R, Matsuda J, Ishida N (2009) PERIOD2 is a circadian negative regulator of PAI-1 gene expression in mice. J Mol Cell Cardiol 46:545–552PubMedCrossRef

Polidarová L, Soták M, Sládek M, Pacha J, Sumová A (2009) Temporal gradient in the clock gene and cell-cycle checkpoint kinase Wee1 expression along the gut. Chronobiol Int 26:607–620PubMedCrossRef

Rodrigues RF, Roque L, Krug T, Leite V (2007) Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br J Cancer 96(8):1237–1245PubMedCrossRef

Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A (2005) Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 93:799–803PubMedCrossRef

Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A (2006) Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci 97:395–399PubMedCrossRef

Samarakoon R, Higgins CE, Higgins SP, Higgins PJ (2009) TGF-beta1-induced expression of the poor prognosis SERPINE1/PAI-1 gene requires EGFR signaling: a new target for anti-EGFR therapy. J Oncol 2009:342391PubMed

Sasaki M, Yoshitane H, Du NH, Okano T, Fukada Y (2009) Preferential inhibition of BMAL2-CLOCK activity by PER2 reemphasizes its negative role and a positive role of BMAL2 in the circadian transcription. J Biol Chem 284:25149–25159PubMedCrossRef

Schibler U, Sassone-Corsi P (2002) A web of circadian pacemakers. Cell 111:919–922PubMedCrossRef

Schoenhard JA, Eren M, Johnson CH, Vaughan DE (2002) Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization. Am J Physiol Cell Physiol 283:C103–C114PubMed

Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE (2003) Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol 35:473–481PubMedCrossRef

Schwimmer H, Mursu N, Haim A (2010) Effects of light and melatonin treatment on body temperature and melatonin secretion daily rhythms in a diurnal rodent, the fat sand rat. Chronobiol Int 27:1401–1419PubMedCrossRef

Shi S, Hida A, McGuinness OP, Wasserman DH, Yamazaki S, Johnson CH (2010) Circadian clock gene Bmal1 is not essential; functional replacement with its paralog, Bmal2. Curr Biol 20:316–321PubMedCrossRef

Sier CF, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PH, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJ, Lamers CB (1994) Inactive urokinase and increased levels of its inhibitors type 1 in colorectal cancer liver metastasis. Gastroenterology 107:1449–1456PubMed

Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Fockens JA, Berns EM (2007) Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck 29:341–350PubMedCrossRef

Takahashi JS, Hong HK, Ko CH, McDearmon EL (2008) The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 9:764–775PubMedCrossRef

Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, Arnogianaki N, Plataniotis G, Yotis J, Agnanti N (2004) Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 205:97–106PubMedCrossRef

Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O’Donoughe DP (2004) Expression of cathepsin B and L antigen and activity is associated with early colorectal progression. Eur J Cancer 40:1610–1616PubMedCrossRef

Vial D, McKeown-Longo PJ (2008) PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins. J Cell Sci 121(Pt 10):1661–1670PubMedCrossRef

Wille JJ Jr (2003) Circadian rhythm of tumor promotion in the two-stage model of mouse tumorigenesis. Cancer Lett 190:143–149PubMedCrossRef

Wright CM, Dent OF, Newland RC, Barker M, Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA (2005) Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut 54:103–108PubMedCrossRef

Yamamura Y, Yano I, Kudo T, Shibata S (2010) Time-dependent inhibitory effect of lipopolysaccharide injection on Per1 and Per2 gene expression in the mouse heart and liver. Chronobiol Int 27:213–232PubMedCrossRef

Yeh CT, Lu SC, Tseng IC, Lai HY, Tsao ML, Huang SF, Liaw YF (2003) Antisense overexpression of BMAL2 enhances cell proliferation. Oncogene 22:5306–5314PubMedCrossRef

Titel: ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer
verfasst von: Gianluigi Mazzoccoli
Valerio Pazienza
Anna Panza
Maria Rosa Valvano
Giorgia Benegiamo
Manlio Vinciguerra
Angelo Andriulli
Ada Piepoli
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1126-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Trends in incidence, tumour sites and tumour stages of oral and pharyngeal cancer in Northern Germany

Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients

RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines

Etoposide, vincristine, doxorubicin and dexamethasone (EVAD) combination chemotherapy as second-line treatment for advanced AIDS-related Kaposi’s sarcoma

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells

Functional outcome after different oncological interventions in head and neck cancer patients

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie